Composition containing long-chain unsaturated fatty acid amide and kasugamycin and preparation method thereof

Abstract

The invention relates to the field of agricultural antibiosis, in particular to a composition containing long-chain unsaturated fatty acid amide and kasugamycin and a preparation method thereof.The composition comprises the long-chain unsaturated fatty acid amide, modified kasugamycin and other effective ingredients, the long-chain unsaturated fatty acid amide is specifically combined with T3SS core protein HrcC, and the modified kasugamycin is specifically combined with T3SS core protein HrcC; the injection body assembly is blocked, and the effect protein secretion is inhibited; kasugamycin can cause that bacteria cannot synthesize necessary functional proteins and die. The two components have a synergistic effect and can exert power at the same time from two aspects of inhibiting bacterial toxicity secretion and basic metabolism, so that the control effect on plant bacterial diseases is effectively improved. In practical application, the composition can greatly reduce damage of diseases to crops, guarantee healthy growth of the crops and improve the yield and quality of the crops, and has a wide application prospect.

Description

Technical Field

[0001] The present invention relates to the field of agricultural antibacterials, and particularly to a composition containing long-chain unsaturated fatty acid amide and kasugamycin and a preparation method thereof. Background Art

[0002] Plant bacterial diseases seriously threaten the safety of agricultural production. Gram-negative bacterial pathogens (such as Pseudomonas syringae, Ralstonia solanacearum, etc.) rely on the type III secretion system (T3SS) to inject virulence proteins into host cells, destroying the plant immune system, which is an important pathogenic mechanism leading to crop yield reduction. T3SS is mediated by an injector formed by the assembly of multiple proteins (such as the outer membrane ring protein HrcC), whose structure is conserved and function is crucial, becoming an important target for new antibacterial agents. However, traditional antibacterial strategies mainly rely on a single mechanism of action, such as inhibiting bacterial growth or cell wall synthesis. Long-term use is likely to cause drug resistance, and there are limited specific intervention means for virulence systems such as T3SS.

[0003] In recent years, the discovery of plant-derived virulence metabolites has provided new ideas for disease control. Long-chain unsaturated fatty acid amide compounds such as erucamide can specifically bind to the core protein HrcC of T3SS, block the assembly of the injector, inhibit the secretion of effector proteins, thereby weakening bacterial pathogenicity. Such compounds have broad-spectrum antivirulence activities, inhibiting the T3SS secretion of various pathogenic bacteria such as Pseudomonas syringae and Xanthomonas campestris pv. campestris, and are induced to accumulate through pathogen-associated molecular patterns (PAMPs) in plants such as Arabidopsis thaliana and rice, which is an important part of plant innate immunity. On the other hand, kasugamycin, as an aminoglycoside antibiotic, inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome and has antibacterial activity against a variety of plant pathogenic bacteria. However, when used alone, there are problems such as a single action target and easy development of drug resistance after long-term application.

[0004] Therefore, according to the above related technologies, it is urgent to develop a composition containing long-chain unsaturated fatty acid amide and kasugamycin and a preparation method thereof. Summary of the Invention

[0005] In view of this, the purpose of the present invention is to provide a composition containing long-chain unsaturated fatty acid amide and kasugamycin and a preparation method thereof, so as to provide a composite preparation with both a new antivirulence mechanism and a traditional antibacterial effect, in order to break through the existing prevention and control bottleneck.

[0006] Based on the above purpose, the present invention provides a composition containing long-chain unsaturated fatty acid amide and kasugamycin and a preparation method thereof.

[0007] A composition containing long-chain unsaturated fatty acid amide and kasugamycin, and the composition containing long-chain unsaturated fatty acid amide and kasugamycin is used for preparing any one of wettable powders, suspension concentrates, emulsifiable concentrates, microemulsions and water dispersible granules; The composition containing long-chain unsaturated fatty acid amide and kasugamycin comprises the following active ingredients: long-chain unsaturated fatty acid amide, kasugamycin.

[0008] Preferably, the long-chain unsaturated fatty acid amide is one or more of erucamide, (E)-13-docosenamide, 13-tetradecenoic acid amide.

[0009] Preferably, the kasugamycin is any one of kasugamycin technical and modified kasugamycin.

[0010] The modified kasugamycin is plasma-activated kasugamycin.

[0011] Preferably, the preparation process of the modified kasugamycin is as follows: A dielectric barrier discharge device is used to prepare cold plasma-activated water. In the reactor, a quartz plate with a diameter of 100 mm and a thickness of 1 mm is placed on the upper layer of the electrode, and the lower layer reaction tank is filled with 10 ml of distilled water. The variable voltage is adjusted to make the input voltage reach 40 V at 25 °C. The discharge distance is controlled to be 6 mm by a sine high-voltage power supply with a frequency of 10 KHz, the treatment time is set to 120 s, and the input current is maintained at 1.0 ± 0.05 A, so as to obtain cold plasma-activated water. The principle is that active substances such as reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated by plasma discharge dissolve in water, endowing water with unique chemical properties; the weighed kasugamycin is added to a container containing cold plasma-activated water, and stirred to make it fully dissolve, and reacted at 35 °C for 60 min. During the reaction process, the active substances in the cold plasma-activated water react with the kasugamycin molecules by oxidation, addition, etc., changing the chemical structure of kasugamycin and thus enhancing its antibacterial activity.

[0012] Preferably, the dosage ratio of kasugamycin to cold plasma-activated water is 10 - 20 g: 80 - 100 mL.

[0013] A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin, the composition containing long-chain unsaturated fatty acid amide and kasugamycin is the composition containing long-chain unsaturated fatty acid amide and kasugamycin as described above, and the preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin when used for preparing wettable powder is as follows: Mix kasugamycin, long-chain unsaturated fatty acid amide, dispersant, wetting agent, thickener, preservative and filler evenly, and grind them to a particle size of ≤5 μm by air flow pulverization, and pass through a 200-mesh sieve to obtain a composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder.

[0014] Preferably, the mass ratio of kasugamycin, long-chain unsaturated fatty acid amide, dispersant, wetting agent, thickener, preservative and filler is 14-16:7-9:4-6:2-4:0.7-0.9:0.15-0.25:67-69.

[0015] Preferably, the dispersant is sodium lignosulfonate, the wetting agent is triphenylethylene phenol polyoxyethylene ether phosphate, the thickener is bentonite, the preservative is benzoic acid, and the filler is diatomite.

[0016] A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. When the composition containing long-chain unsaturated fatty acid amide and kasugamycin is used for preparing a suspension concentrate, the preparation process is as follows: Add kasugamycin, long-chain unsaturated fatty acid amide, dispersant and wetting agent to deionized water, stir and disperse evenly, grind with a sand mill to an average particle size of ≤2 μm, and add thickener and stabilizer to obtain a composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a suspension concentrate.

[0017] Preferably, the mass ratio of kasugamycin, long-chain unsaturated fatty acid amide, dispersant, wetting agent, deionized water, thickener and stabilizer is 9-11:4-6:3-5:2-4:72-73:0.45-0.55:4-6.

[0018] Preferably, the dispersant is polycarboxylate, the wetting agent is sodium dodecyl sulfate, the thickener is xanthan gum, and the stabilizer is propylene glycol.

[0019] A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. When the composition containing long-chain unsaturated fatty acid amide and kasugamycin is used for preparing an emulsifiable concentrate, the preparation process is as follows: Add long-chain unsaturated fatty acid amide and kasugamycin to a solvent, stir to dissolve them fully, then add an emulsifier, and continue to stir and mix evenly to obtain a composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing an emulsifiable concentrate.

[0020] Preferably, the mass ratio of long-chain unsaturated fatty acid amide, kasugamycin, solvent and emulsifier is 87-89:10-14:55-65:18-22; Preferably, the solvent is xylene, and the emulsifier is castor oil polyoxyethylene ether.

[0021] A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin, and the preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin when used for preparing a microemulsion is as follows: First, dissolve the long-chain unsaturated fatty acid amide and kasugamycin in a cosolvent to form a uniform solution, then add an emulsifier under stirring conditions, continue stirring to fully mix the system, and finally add water to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a microemulsion.

[0022] Preferably, the mass ratio of the long-chain unsaturated fatty acid amide, kasugamycin, cosolvent, emulsifier and water is 8-12:8-12:4-6:14-16:58-62; Preferably, the cosolvent is propylene glycol and the emulsifier is Tween-80.

[0023] A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin, and the preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin when used for preparing a water dispersible granule is as follows: Mix the long-chain unsaturated fatty acid amide, kasugamycin, dispersant, wetting agent, disintegrant, binder and filler evenly, crush the mixture to a particle size of 0.25-0.42 mm by air flow pulverization, and granulate by spray drying to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule.

[0024] The mass ratio of the long-chain unsaturated fatty acid amide, kasugamycin, dispersant, wetting agent, disintegrant, binder and filler is 14-16:8-12:4-6:2-4:4-6:1.8-2.2:58-62.

[0025] The dispersant is sodium lignosulfonate, the wetting agent is sodium dodecyl sulfate, the disintegrant is bentonite, the binder is polyvinyl alcohol, and the filler is white carbon black.

[0026] Advantages of the present invention: The present invention provides a composition containing long-chain unsaturated fatty acid amide and kasugamycin and a preparation method thereof. By compounding the long-chain unsaturated fatty acid amide and kasugamycin and developing various dosage forms, the present invention shows various beneficial effects in the prevention and control of plant bacterial diseases: 1. Synergistic antibacterial effect, highly effective in preventing and controlling diseases: Long-chain unsaturated fatty acid amides specifically bind to the core protein HrcC of the T3SS, blocking the assembly of the injector and inhibiting the secretion of effector proteins; while kasugamycin can be absorbed through plant leaves and roots and conducted throughout the body, with both protective and therapeutic effects, and can enter bacterial cells through contact or systemic absorption, directly inhibiting their growth and reproduction.

[0027] 2. Delay drug resistance and extend the lifespan of the medicament: The long-term use of traditional single antibacterial agents is likely to cause bacteria to develop drug resistance. However, in the present invention, the long-chain unsaturated fatty acid amides and kasugamycin have different action targets. It is difficult for bacteria to resist both of them simultaneously through a single drug resistance mechanism, greatly delaying the generation of drug resistance, extending the service life of the medicament, reducing the failure of prevention and control caused by drug resistance, and providing a reliable guarantee for the continuous and effective prevention and control of plant bacterial diseases in agricultural production.

[0028] 3. Diverse dosage forms to meet different needs: The composition of the present invention can be prepared into various dosage forms such as wettable powders, suspensions, emulsifiable concentrates, microemulsions, and water-dispersible granules. Different dosage forms have different characteristics and can meet the requirements of different application methods, crop types, and disease conditions. Wettable powders are convenient for storage and use, suspensions have good stability and strong dispersibility, emulsifiable concentrates and microemulsions can quickly disperse in water to form uniform emulsions, and water-dispersible granules have a fast disintegration rate and high suspension rate. Growers can flexibly select the appropriate dosage form according to the actual situation to improve the use efficiency and control effect of the medicament.

[0029] 4. Green and environmentally friendly, reducing environmental pressure: Long-chain unsaturated fatty acid amides are plant-derived anti-toxic compounds that play a role in plant natural immunity; kasugamycin itself has low residues. The combined use of the two reduces the overall usage of chemical pesticides, reduces pollution to the environment such as soil, water bodies, and air, and has less impact on non-target organisms, conforming to the concepts of green agriculture and sustainable development, and contributing to the protection of the balance and stability of the ecological environment.

[0030] 5. The preparation process is feasible and suitable for industrial production: The preparation methods of each dosage form in the present invention are clear and relatively simple to operate, and the raw materials and equipment involved are relatively common in the agricultural chemical industry. For example, processes such as air-flow pulverization, sand mill grinding, and spray drying are all mature industrial production technologies, and the mass ratio of the raw materials has also been reasonably designed, facilitating large-scale production and quality control, suitable for industrial promotion and application, and capable of providing sufficient products for the market to meet the needs of agricultural production for highly effective plant bacterial disease control agents. Detailed implementation mode

[0031] To make the objectives, technical solutions, and advantages of the present invention clearer and more understandable, the following further details the present invention in combination with specific embodiments.

[0032] Example 1: A preparation method of modified kasugamycin, comprising the following steps: Cold plasma-activated water was prepared using a dielectric barrier discharge device. In the reactor, a quartz plate with a diameter of 100 mm and a thickness of 1 mm was placed on the upper layer of the electrode, and 10 ml of distilled water was filled in the lower reaction tank. The variable voltage was adjusted to reach an input voltage of 40 V at 25 °C. The discharge distance was controlled at 6 mm by a sinusoidal high-voltage power supply with a frequency of 10 kHz, and the treatment time was set to 120 s, maintaining the input current at 1.0 ± 0.05 A, thereby obtaining cold plasma-activated water. The principle is that active substances such as reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated by plasma discharge dissolve in water, endowing the water with unique chemical properties; 10 g of weighed kasugamycin was added to a container containing 80 mL of cold plasma-activated water, and stirred to dissolve it completely. The reaction was carried out at 35 °C for 60 min. During the reaction, the active substances in the cold plasma-activated water reacted with the kasugamycin molecules, such as oxidation and addition reactions, changing the chemical structure of kasugamycin, and thus enhancing its antibacterial activity, obtaining modified kasugamycin.

[0033] Example 2: A preparation method of modified kasugamycin, comprising the following steps: Cold plasma-activated water was prepared using a dielectric barrier discharge device. In the reactor, a quartz plate with a diameter of 100 mm and a thickness of 1 mm was placed on the upper layer of the electrode, and 10 ml of distilled water was filled in the lower reaction tank. The variable voltage was adjusted to reach an input voltage of 40 V at 25 °C. The discharge distance was controlled at 6 mm by a sinusoidal high-voltage power supply with a frequency of 10 kHz, and the treatment time was set to 120 s, maintaining the input current at 1.0 ± 0.05 A, thereby obtaining cold plasma-activated water. The principle is that active substances such as reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated by plasma discharge dissolve in water, endowing the water with unique chemical properties; 15 g of weighed kasugamycin was added to a container containing 90 mL of cold plasma-activated water, and stirred to dissolve it completely. The reaction was carried out at 35 °C for 60 min. During the reaction, the active substances in the cold plasma-activated water reacted with the kasugamycin molecules, such as oxidation and addition reactions, changing the chemical structure of kasugamycin, and thus enhancing its antibacterial activity, obtaining modified kasugamycin.

[0034] Example 3: A preparation method of modified kasugamycin, comprising the following steps: Cold plasma-activated water is prepared using a dielectric barrier discharge device. In the reactor, a quartz plate with a diameter of 100 mm and a thickness of 1 mm is placed on the upper layer of the electrode, and 10 ml of distilled water is filled in the lower reaction tank. The variable voltage is adjusted to reach an input voltage of 40 V at 25 °C. The discharge distance is controlled at 6 mm by a sinusoidal high-voltage power supply with a frequency of 10 kHz, the treatment time is set at 120 s, and the input current is maintained at 1.0 ± 0.05 A, thereby obtaining cold plasma-activated water. The principle is that reactive oxygen species (ROS), reactive nitrogen species (RNS) and other active substances generated by plasma discharge dissolve into the water, endowing the water with unique chemical properties; 20 g of the weighed kasugamycin is added to a container containing 100 mL of cold plasma-activated water, and stirred to dissolve it fully. The reaction is carried out at 35 °C for 60 min. During the reaction process, the active substances in the cold plasma-activated water react with the kasugamycin molecules, such as oxidation and addition reactions, to change the chemical structure of kasugamycin, and thus enhance its antibacterial activity, obtaining modified kasugamycin.

[0035] Example 4: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder is as follows: 14 g of kasugamycin, 7 g of erucic acid amide, 4 g of sodium lignosulfonate, 2 g of triphenyl ethylene phenol polyoxyethylene ether phosphate, 0.7 g of bentonite, 0.15 g of benzoic acid and 67 g of diatomite are mixed evenly, pulverized by air flow to a particle size ≤ 5 μm, and sieved through a 200-mesh sieve to obtain a composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder.

[0036] Example 5: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder is as follows: 15 g of kasugamycin, 8 g of (E)-13-docosenamide, 5 g of sodium lignosulfonate, 3 g of triphenyl ethylene phenol polyoxyethylene ether phosphate, 0.8 g of bentonite, 0.2 g of benzoic acid and 68 g of diatomite are mixed evenly, pulverized by air flow to a particle size ≤ 5 μm, and sieved through a 200-mesh sieve to obtain a composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder.

[0037] Example 6: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder is as follows: Mix 16 g of kasugamycin, 9 g of 13 - tetradecenoic acid amide, 6 g of sodium lignosulfonate, 4 g of triphenyl ethylene phenol polyoxyethylene ether phosphate, 0.9 g of bentonite, 0.25 g of benzoic acid and 69 g of diatomaceous earth evenly, and pulverize them by air flow to a particle size of ≤5 μm, then pass through a 200 - mesh sieve to obtain a composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder.

[0038] Example 7: A preparation method of a composition containing long - chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing suspension concentrate is as follows: Add 9 g of kasugamycin, 4 g of erucic acid amide, 3 g of polycarboxylate and 2 g of sodium dodecyl sulfate into 72 g of deionized water, stir and disperse evenly, grind with a sand mill to an average particle size of ≤2 μm, add 0.45 g of xanthan gum and 4 g of propylene glycol to obtain a composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing suspension concentrate.

[0039] Example 8: A preparation method of a composition containing long - chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing suspension concentrate is as follows: Add 10 g of kasugamycin, 5 g of (E) - 13 - docosenamide, 4 g of polycarboxylate and 3 g of sodium dodecyl sulfate into 72.5 g of deionized water, stir and disperse evenly, grind with a sand mill to an average particle size of ≤2 μm, add 0.5 g of xanthan gum and 5 g of propylene glycol to obtain a composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing suspension concentrate.

[0040] Example 9: A preparation method of a composition containing long - chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing suspension concentrate is as follows: Add 11 g of kasugamycin, 6 g of 13 - tetradecenoic acid amide, 5 g of polycarboxylate and 4 g of sodium dodecyl sulfate into 73 g of deionized water, stir and disperse evenly, grind with a sand mill to an average particle size of ≤2 μm, add 0.55 g of xanthan gum and 6 g of propylene glycol to obtain a composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing suspension concentrate.

[0041] Example 10: A preparation method of a composition containing long - chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing emulsifiable concentrate is as follows: 87 g of erucamide and 10 g of kasugamycin were added to 55 g of xylene, stirred to dissolve them thoroughly, then 18 g of castor oil polyoxyethylene ether was added, and stirring was continued to mix evenly, obtaining a composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing emulsifiable concentrate.

[0042] Example 11: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. When the composition containing long-chain unsaturated fatty acid amide and kasugamycin is used for preparing emulsifiable concentrate, the preparation process is as follows: 88 g of (E)-13-docosenamide and 12 g of kasugamycin were added to 60 g of xylene, stirred to dissolve them thoroughly, then 20 g of castor oil polyoxyethylene ether was added, and stirring was continued to mix evenly, obtaining a composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing emulsifiable concentrate.

[0043] Example 12: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. When the composition containing long-chain unsaturated fatty acid amide and kasugamycin is used for preparing emulsifiable concentrate, the preparation process is as follows: 89 g of 13-tetradecenoic acid amide and 14 g of kasugamycin were added to 65 g of xylene, stirred to dissolve them thoroughly, then 22 g of castor oil polyoxyethylene ether was added, and stirring was continued to mix evenly, obtaining a composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing emulsifiable concentrate.

[0044] Example 13: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. When the composition containing long-chain unsaturated fatty acid amide and kasugamycin is used for preparing microemulsion, the preparation process is as follows: First, 8 g of erucamide and 8 g of kasugamycin were dissolved in 4 g of propylene glycol to form a uniform solution, then 14 g of Tween-80 was added under stirring conditions, and stirring was continued to make the system mix thoroughly. Finally, 58 g of water was added, obtaining a composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing microemulsion.

[0045] Example 14: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. When the composition containing long-chain unsaturated fatty acid amide and kasugamycin is used for preparing microemulsion, the preparation process is as follows: First, 10 g of (E)-13-docosenamide and 10 g of kasugamycin were dissolved in 5 g of propylene glycol to form a uniform solution, then 15 g of Tween-80 was added under stirring conditions, and stirring was continued to make the system mix thoroughly. Finally, 60 g of water was added, obtaining a composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing microemulsion.

[0046] Example 15: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a microemulsion is as follows: First, dissolve 12 g of 13-tetradecenoic acid amide and 12 g of kasugamycin in 6 g of propylene glycol to form a uniform solution. Then, add 16 g of Tween-80 under stirring conditions and continue stirring to fully mix the system. Finally, add 62 g of water to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a microemulsion.

[0047] Example 16: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule is as follows: Mix 14 g of erucic acid amide, 8 g of kasugamycin, 4 g of sodium lignosulfonate, 2 g of sodium dodecyl sulfate, 4 g of bentonite, 1.8 g of polyvinyl alcohol and 58 g of white carbon black evenly. Crush the mixture to a particle size of 0.25 - 0.42 mm by air flow crushing and granulate by spray drying method to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule.

[0048] Example 17: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule is as follows: Mix 15 g of (E)-13-docosenamide, 10 g of kasugamycin, 5 g of sodium lignosulfonate, 3 g of sodium dodecyl sulfate, 5 g of bentonite, 2 g of polyvinyl alcohol and 60 g of white carbon black evenly. Crush the mixture to a particle size of 0.25 - 0.42 mm by air flow crushing and granulate by spray drying method to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule.

[0049] Example 18: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule is as follows: Mix 16 g of 13-tetradecenoic acid amide, 12 g of kasugamycin, 6 g of sodium lignosulfonate, 4 g of sodium dodecyl sulfate, 6 g of bentonite, 2.2 g of polyvinyl alcohol and 62 g of white carbon black evenly. Crush the mixture to a particle size of 0.25 - 0.42 mm by air flow crushing and granulate by spray drying method to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule.

[0050] Example 19: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder is as follows: Mix 14 g of the modified kasugamycin prepared in Example 1, 7 g of erucamide, 4 g of sodium lignosulfonate, 2 g of triphenyl ethylene phenol polyoxyethylene ether phosphate, 0.7 g of bentonite, 0.15 g of benzoic acid and 67 g of diatomite evenly, grind them by air flow to a particle size ≤ 5 μm, and pass through a 200-mesh sieve to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder.

[0051] Example 20: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder is as follows: Mix 15 g of the modified kasugamycin prepared in Example 2, 8 g of (E)-13-docosenamide, 5 g of sodium lignosulfonate, 3 g of triphenyl ethylene phenol polyoxyethylene ether phosphate, 0.8 g of bentonite, 0.2 g of benzoic acid and 68 g of diatomite evenly, grind them by air flow to a particle size ≤ 5 μm, and pass through a 200-mesh sieve to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder.

[0052] Example 21: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder is as follows: Mix 16 g of the modified kasugamycin prepared in Example 3, 9 g of 13-tetradecenoic acid amide, 6 g of sodium lignosulfonate, 4 g of triphenyl ethylene phenol polyoxyethylene ether phosphate, 0.9 g of bentonite, 0.25 g of benzoic acid and 69 g of diatomite evenly, grind them by air flow to a particle size ≤ 5 μm, and pass through a 200-mesh sieve to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder.

[0053] Example 22: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing suspension concentrate is as follows: Add 9 g of the modified kasugamycin prepared in Example 1, 4 g of erucamide, 3 g of polycarboxylate and 2 g of sodium dodecyl sulfate to 72 g of deionized water, stir and disperse evenly, grind them by a sand mill to an average particle size ≤ 2 μm, add 0.45 g of xanthan gum and 4 g of propylene glycol to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing suspension concentrate.

[0054] Example 23: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a suspending agent is as follows: 10 g of the modified kasugamycin prepared in Example 2, 5 g of (E)-13-docosenamide, 4 g of polycarboxylate, and 3 g of sodium dodecyl sulfate were added to 72.5 g of deionized water, stirred and dispersed evenly, ground by a sand mill until the average particle size ≤ 2 μm, 0.5 g of xanthan gum and 5 g of propylene glycol were added to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a suspending agent.

[0055] Example 24: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a suspending agent is as follows: 11 g of the modified kasugamycin prepared in Example 3, 6 g of 13-tetradecenoic acid amide, 5 g of polycarboxylate, and 4 g of sodium dodecyl sulfate were added to 73 g of deionized water, stirred and dispersed evenly, ground by a sand mill until the average particle size ≤ 2 μm, 0.55 g of xanthan gum and 6 g of propylene glycol were added to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a suspending agent.

[0056] Example 25: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing an emulsifiable concentrate is as follows: 87 g of erucamide and 10 g of the modified kasugamycin prepared in Example 1 were added to 55 g of xylene, stirred to dissolve completely, then 18 g of castor oil polyoxyethylene ether was added, and stirring was continued to mix evenly to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing an emulsifiable concentrate.

[0057] Example 26: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing an emulsifiable concentrate is as follows: 88 g of (E)-13-docosenamide and 12 g of the modified kasugamycin prepared in Example 2 were added to 60 g of xylene, stirred to dissolve completely, then 20 g of castor oil polyoxyethylene ether was added, and stirring was continued to mix evenly to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing an emulsifiable concentrate.

[0058] Example 27: A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing an emulsifiable concentrate is as follows: 89 g of 13 - tetradecenoic acid amide and 14 g of the modified kasugamycin prepared in Example 3 were added to 65 g of xylene, stirred to dissolve them thoroughly, then 22 g of castor oil polyoxyethylene ether was added, and stirring was continued to mix evenly, obtaining a composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing emulsifiable concentrate.

[0059] Example 28: A preparation method of a composition containing long - chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing microemulsion is as follows: First, 8 g of erucic acid amide and 8 g of the modified kasugamycin prepared in Example 1 were dissolved in 4 g of propylene glycol to form a uniform solution. Then, 14 g of Tween - 80 was added under stirring conditions, and stirring was continued to make the system mix thoroughly. Finally, 58 g of water was added, obtaining a composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing microemulsion.

[0060] Example 29: A preparation method of a composition containing long - chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing microemulsion is as follows: First, 10 g of (E) - 13 - docosenamide and 10 g of the modified kasugamycin prepared in Example 2 were dissolved in 5 g of propylene glycol to form a uniform solution. Then, 15 g of Tween - 80 was added under stirring conditions, and stirring was continued to make the system mix thoroughly. Finally, 60 g of water was added, obtaining a composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing microemulsion.

[0061] Example 30: A preparation method of a composition containing long - chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing microemulsion is as follows: First, 12 g of 13 - tetradecenoic acid amide and 12 g of the modified kasugamycin prepared in Example 3 were dissolved in 6 g of propylene glycol to form a uniform solution. Then, 16 g of Tween - 80 was added under stirring conditions, and stirring was continued to make the system mix thoroughly. Finally, 62 g of water was added, obtaining a composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing microemulsion.

[0062] Example 31: A preparation method of a composition containing long - chain unsaturated fatty acid amide and kasugamycin. The preparation process of the composition containing long - chain unsaturated fatty acid amide and kasugamycin for preparing water - dispersible granules is as follows: Mix 14 g of erucamide, 8 g of the modified kasugamycin prepared in Example 1, 4 g of sodium lignosulfonate, 2 g of sodium dodecyl sulfate, 4 g of bentonite, 1.8 g of polyvinyl alcohol, and 58 g of silica white evenly, and pulverize the mixture to a particle size of 0.25 - 0.42 mm by air jet milling. Granulate by spray drying to obtain a composition containing a long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule.

[0063] Example 32: A preparation method of a composition containing a long-chain unsaturated fatty acid amide and kasugamycin. When the composition containing a long-chain unsaturated fatty acid amide and kasugamycin is used for preparing a water dispersible granule, the preparation process is as follows: Mix 15 g of (E)-13-docosenamide, 10 g of the modified kasugamycin prepared in Example 2, 5 g of sodium lignosulfonate, 3 g of sodium dodecyl sulfate, 5 g of bentonite, 2 g of polyvinyl alcohol, and 60 g of silica white evenly, and pulverize the mixture to a particle size of 0.25 - 0.42 mm by air jet milling. Granulate by spray drying to obtain a composition containing a long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule.

[0064] Example 33: A preparation method of a composition containing a long-chain unsaturated fatty acid amide and kasugamycin. When the composition containing a long-chain unsaturated fatty acid amide and kasugamycin is used for preparing a water dispersible granule, the preparation process is as follows: Mix 16 g of 13-tetradecenoic acid amide, 12 g of the modified kasugamycin prepared in Example 3, 6 g of sodium lignosulfonate, 4 g of sodium dodecyl sulfate, 6 g of bentonite, 2.2 g of polyvinyl alcohol, and 62 g of silica white evenly, and pulverize the mixture to a particle size of 0.25 - 0.42 mm by air jet milling. Granulate by spray drying to obtain a composition containing a long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule.

[0065] Comparative Example 1: In this comparative example, compared with Example 4, "erucamide" was not added in the preparation process of the composition containing a long-chain unsaturated fatty acid amide and kasugamycin for preparing a wettable powder, and the remaining steps and parameters were the same. This comparative example will not be repeated here, and finally a composition containing a long-chain unsaturated fatty acid amide and kasugamycin for preparing a wettable powder was obtained.

[0066] Comparative Example 2: In this comparative example, compared with Example 7, "(E)-13-docosenamide" was not added in the preparation process of the composition containing a long-chain unsaturated fatty acid amide and kasugamycin for preparing a wettable powder, and the remaining steps and parameters were the same. This comparative example will not be repeated here, and finally a composition containing a long-chain unsaturated fatty acid amide and kasugamycin for preparing a wettable powder was obtained.

[0067] Performance test: 1. Perform the following performance tests on the products (wettable powder dosage form) prepared in Example 4, Examples 19 - 21, and Comparative Example 1: 1.1 Antibacterial performance test: Using the agar diffusion method, pour the melted culture medium into a sterile petri dish. After it solidifies, use a pipette to suck an appropriate amount of bacterial suspension and evenly coat it on the surface of the culture medium. Place Oxford cups on the culture medium, and add equal amounts of the wettable powder solutions of Example 4, Examples 19 - 21, and Comparative Example 1 (prepared into the same concentration with sterile water) into the Oxford cups respectively. After placing the petri dish in an incubator at 28°C for 24 - 48 h, measure the diameter of the antibacterial zone. Set three replicates for each treatment and record the average value of each group. The results are shown in Table 1 below: Table 1 Summary of antibacterial test results in Examples 19 - 21 and Comparative Example 1 Project Pseudomonas syringae Xanthomonas campestris pv. campestris Example 19 22.8 mm 20.9 mm Example 20 22.1 mm 19.8 mm Example 21 21.2 mm 19.1 mm Example 4 18.1 mm 16.2 mm Comparative Example 1 15.1 mm 14.2 mm Data analysis: The antibacterial effects of the wettable powders in Example 4, Examples 19 - 21 are significantly better than those in Comparative Example 1. This is because in Example 4, kasugamycin and long-chain unsaturated fatty acid amide are compounded, and in Examples 19 - 21, the modified kasugamycin and long-chain unsaturated fatty acid amide produce a synergistic effect. The modified kasugamycin enhances the ability to interfere with the amino acid metabolism of pathogenic bacteria and inhibit protein synthesis, and the long-chain unsaturated fatty acid amide blocks the assembly of the bacterial T3SS injector and inhibits the secretion of effector proteins. The two work together to inhibit bacterial growth and virulence, indicating that after the compounding of the modified kasugamycin and long-chain unsaturated fatty acid amide, through the dual mechanisms of "inhibiting bacterial protein synthesis + blocking T3SS virulence secretion", the antibacterial effect is significantly enhanced, and the differences in the diameters of the antibacterial zones of different long-chain unsaturated fatty acid amides (erucamide, (E)-13-docosenamide, 13-tetradecenoic acid amide) are small, reflecting the broad-spectrum nature of the anti-virulence activity of this type of compound.

[0068] 1.2 Stability test: 1.2.1 Thermal storage stability test: Place the wettable powder samples prepared in Example 4, Examples 19 - 21, and Comparative Example 1 in a sealed container and store them in a constant temperature incubator at 54°C for 14 days. After taking them out, observe whether there are phenomena such as caking and discoloration of the samples; 1.2.2 Low-temperature stability: Place the samples prepared in Example 4, Examples 19 - 21, and Comparative Example 1 in a low-temperature refrigerator at 0°C and store them for 7 days. After taking them out, observe whether there are phenomena such as crystallization and precipitation, and detect whether their dispersibility is affected after returning to room temperature; The results are shown in Table 2 below: Table 2 Summary of Stability Test Results in Example 4, Examples 19 - 21, and Comparative Example 1 Project Hot storage stability Low temperature stability Example 19 No obvious caking or discoloration No crystallization or precipitation Example 20 No obvious caking or discoloration No crystallization or precipitation Example 21 No obvious caking or discoloration No crystallization or precipitation Example 4 No obvious caking or discoloration No crystallization or precipitation Comparative Example 1 Slight caking A small amount of crystallization Data analysis: As can be seen from Table 2, the stability of Example 4, Examples 19 - 21 is significantly higher than that of Comparative Example 1.

[0069] 2. Perform the following performance tests on the products (suspension concentrate dosage form) prepared in Example 7, Examples 22 - 24: 2.1 Antibacterial performance test (agar diffusion method), and the results are shown in Table 3 below: Table 3 Summary of Antibacterial Test Results in Example 7, Examples 22 - 24 Project Pseudomonas syringae Xanthomonas campestris pv. campestris Example 22 24.1 mm 21 mm Example 23 23.3 mm 20.1 mm Example 24 22.9 mm 19.7 mm Example 7 20.7 mm 18 mm Data analysis: The diameters of the antibacterial zones in Example 7, Examples 22 - 24 are all relatively large, indicating that the compounding of kasugamycin, modified kasugamycin and long-chain unsaturated fatty acid amide has a significant synergistic antibacterial effect, which can simultaneously inhibit bacterial protein synthesis (modified kasugamycin) and type III secretion system (long-chain unsaturated fatty acid amide).

[0070] 2.2 Stability test, and the results are shown in Table 4 below: Table 4 Summary of Stability Test Results in Example 7, Examples 22 - 24 Project Hot storage stability Low temperature stability Example 22 No obvious caking or discoloration No crystallization or precipitation Example 23 No obvious caking or discoloration No crystallization or precipitation Example 24 No obvious caking or discoloration No crystallization or precipitation Example 7 No obvious caking or discoloration No crystallization or precipitation 3. Perform the following performance tests on the products (emulsifiable concentrate dosage form) prepared in Example 10, Examples 25 - 27: 3.1 Antibacterial performance test (agar diffusion method), and the results are shown in Table 5 below: Table 5 Summary of Antibacterial Test Results in Example 10, Examples 25 - 27 Project Pseudomonas syringae Xanthomonas campestris pv. campestris Example 25 22.2 mm 20.4 mm Example 26 21.4 mm 19.5 mm Example 27 20.8 mm 18.9 mm Example 10 18.6 mm 16.8 mm Data analysis: The diameters of the antibacterial zones in Examples 25 - 27 are slightly larger than those in Example 10. It shows that after the compounding of modified kasugamycin and long-chain unsaturated fatty acid amide, the inhibitory effects on Pseudomonas syringae and Xanthomonas campestris are significantly enhanced. This is due to the improved antibacterial activity of modified kasugamycin and the inhibitory effect of long-chain unsaturated fatty acid amide on the bacterial virulence system. The two work together to make the antibacterial effect better than that of single unmodified kasugamycin. Different long-chain unsaturated fatty acid amides have slightly different antibacterial performances, but the overall trend is similar, indicating that when these compounds are compounded with modified kasugamycin, they can all play a certain synergistic antibacterial role.

[0071] 3.2 Stability test, and the results are shown in Table 6 below: Summary of Stability Test Results in Example 10, Examples 25 - 27 Project Emulsification stability Hot storage stability Low temperature stability Example 25 Diluted 200 times, no floating oil or delamination No obvious caking or discoloration No crystallization or precipitation Example 26 Diluted 200 times, no floating oil or delamination No obvious caking or discoloration No crystallization or precipitation Example 27 Diluted 200 times, no floating oil or delamination No obvious caking or discoloration No crystallization or precipitation Example 10 Diluted 200 times, no floating oil or delamination No obvious caking or discoloration No crystallization or precipitation Data Analysis: After dilution by 200 times, there is no floating oil or stratification phenomenon in Example 10, Examples 25 - 27, indicating that the emulsifying stability of the examples is better. This benefits from the good compatibility of castor oil polyoxyethylene ether (emulsifier) with kasugamycin and long-chain unsaturated fatty acid amide in the formula, which can form a stable emulsion system.

[0072] 4. Perform the following performance tests on the products (suspension dosage form) prepared in Example 13, Examples 28 - 30: 4.1 Antibacterial Performance Test (agar diffusion method), and the results are shown in Table 7 below: Table 7 Summary of Antibacterial Test Results in Example 13, Examples 28 - 30 Project Pseudomonas syringae Xanthomonas campestris pv. campestris Example 28 23.1 mm 21.5 mm Example 29 22.3 mm 20.6 mm Example 30 21.7 mm 20 mm Example 13 18.1 mm 17.7 mm Data Analysis: The diameter of the antibacterial circle in Examples 28 - 30 is slightly increased compared with Example 13, reflecting the synergistic antibacterial effect of modified kasugamycin and long-chain unsaturated fatty acid amide. After being activated by cold plasma, the molecular polarity of modified kasugamycin is enhanced, making it easier to penetrate the bacterial cell membrane. Combining with the specific inhibition of T3SS by long-chain unsaturated fatty acid amide, a "bactericidal + anti-toxic" dual effect is formed. The difference in the antibacterial circle of different long-chain unsaturated fatty acid amides is small, indicating that this type of compound has similar synergistic activity when compounded with modified kasugamycin, verifying the universality of the formula design.

[0073] 4.2 Stability Test, and the results are shown in Table 8 below: Table 8 Summary of Stability Test Results in Example 13, Examples 28 - 30 Project Emulsification stability Hot storage stability Low temperature stability Example 28 Diluted 300 times, no delamination Transparent and uniform No crystallization or precipitation Example 29 Diluted 300 times, no delamination Transparent and uniform No crystallization or precipitation Example 30 Diluted 300 times, no delamination Transparent and uniform No crystallization or precipitation Example 13 Diluted 300 times, no delamination Transparent and uniform No crystallization or precipitation Data Analysis: There is no stratification in Example 13, Examples 28 - 30 after dilution by 300 times, indicating that the interfacial compatibility of the compounding system is better and is suitable for uniform dispersion during spray application.

[0074] 5. Perform the following performance tests on the products (suspension dosage form) prepared in Example 16, Examples 31 - 33: 5.1 Antibacterial Performance Test (agar diffusion method), and the results are shown in Table 9 below: Table 9 Summary of Antibacterial Test Results in Example 16, Examples 31 - 33 Project Pseudomonas syringae Xanthomonas campestris pv. campestris Example 31 21.9 mm 20.6 mm Example 32 21.3 mm 19 mm Example 33 20.6 mm 18.8 mm Example 16 17.3 mm 16.1 mm Data analysis: The diameter of the inhibition zone in Examples 31 - 33 is slightly larger than that in Example 16, indicating that the compounding of modified kasugamycin and long-chain unsaturated fatty acid amide has a significant synergistic antibacterial effect, which can simultaneously inhibit bacterial protein synthesis (modified kasugamycin) and the type III secretion system (long-chain unsaturated fatty acid amide).

[0075] 5.2 Stability test, and the results are shown in Table 10 below: Table 10 Summary of stability test results in Example 16, Examples 31 - 33 Project Hot storage stability Low temperature stability Example 31 No caking, good disintegration property No crystallization, good dispersibility Example 32 No caking, good disintegration property No crystallization, good dispersibility Example 33 No caking, good disintegration property No crystallization, good dispersibility Example 16 No caking, good disintegration property No crystallization, good dispersibility The present invention provides a composition containing long-chain unsaturated fatty acid amide and kasugamycin and its preparation method. By compounding long-chain unsaturated fatty acid amide with kasugamycin and developing various dosage forms, the present invention shows various beneficial effects in the prevention and control of plant bacterial diseases: 1. Synergistic antibacterial and highly effective in preventing and controlling diseases: Long-chain unsaturated fatty acid amide specifically binds to the core protein HrcC of T3SS, blocks the assembly of injectisome, and inhibits the secretion of effector proteins; while kasugamycin can be absorbed through plant leaves and roots and conducted throughout the body, having both protective and therapeutic effects, and can enter bacterial cells through contact or systemic absorption to directly inhibit their growth and reproduction; Kasugamycin specifically binds to the 30S subunit of the bacterial ribosome, interferes with the binding process of mRNA to the ribosome, blocks the entry of amino acid - tRNA into the ribosomal A site, inhibits peptide chain elongation, thereby inhibiting protein biosynthesis, and ultimately causing bacteria to be unable to synthesize essential functional proteins (such as enzymes, structural proteins, etc.), ultimately inhibiting bacterial growth or causing bacterial death. In addition, kasugamycin strengthens the antibacterial effect by inhibiting the esterase system and interfering with the uptake and utilization of amino acids by pathogenic bacteria, further blocking the supply of raw materials for protein synthesis.

[0076] The modified kasugamycin is activated by cold plasma-activated water, enhancing its ability to interfere with the amino acid metabolism of pathogenic bacteria and inhibit protein synthesis. The two work synergistically, and can simultaneously exert force from two levels of inhibiting bacterial virulence secretion and basic metabolism. The inhibitory effect on various pathogenic bacteria such as Pseudomonas syringae and Xanthomonas campestris is significantly better than that of single components, effectively improving the prevention and control effect on plant bacterial diseases. In practical applications, it can greatly reduce the damage of diseases to crops, ensure the healthy growth of crops, and improve the yield and quality of agricultural products.

[0077] 2. Delay drug resistance and extend the lifespan of the agent: When traditional single antibacterial agents are used for a long time, bacteria are prone to develop drug resistance. However, in the present invention, the long-chain unsaturated fatty acid amide and the modified kasugamycin have different action targets. It is difficult for bacteria to resist both of them through a single drug resistance mechanism simultaneously, which greatly delays the generation of drug resistance, extends the service life of the agent, reduces the cases of control failure caused by drug resistance, and provides a reliable guarantee for the continuous and effective control of plant bacterial diseases in agricultural production.

[0078] 3. Diverse dosage forms to meet different needs: The composition of the present invention can be prepared into various dosage forms such as wettable powders, suspensions, emulsifiable concentrates, microemulsions, and water-dispersible granules. Different dosage forms have different characteristics and can meet the requirements of different application methods, crop types, and disease conditions. Wettable powders are convenient for storage and use, suspensions have good stability and strong dispersibility, emulsifiable concentrates and microemulsions can quickly disperse in water to form a uniform emulsion, and water-dispersible granules have a fast disintegration rate and a high suspension rate. Growers can flexibly choose the appropriate dosage form according to the actual situation to improve the use efficiency and control effect of the agent.

[0079] 4. Green and environmentally friendly, reducing environmental pressure: Long-chain unsaturated fatty acid amide is a plant-derived antiviral compound that plays a role in plant innate immunity; kasugamycin itself has low residues, and its usage may be further reduced after being modified by cold plasma-activated water. The combination of the two reduces the overall usage of chemical pesticides, reduces the pollution of the environment such as soil, water bodies, and air, and has less impact on non-target organisms, which conforms to the concepts of green agriculture and sustainable development and helps to protect the balance and stability of the ecological environment.

[0080] 5. The preparation process is feasible and suitable for industrial production: The preparation methods of each dosage form in the present invention are clear and relatively easy to operate. The raw materials and equipment involved are relatively common in the field of agrochemicals. For example, processes such as air-flow pulverization, sand mill grinding, and spray drying are all mature industrial production technologies, and the mass ratios of the raw materials are also reasonably designed, which are convenient for large-scale production and quality control, suitable for industrial promotion and application, and can provide sufficient products for the market to meet the needs of agricultural production for highly efficient plant bacterial disease control agents.

[0081] Among them, the ROS in cold plasma-activated water has strong oxidizing properties. Kasugamycin is an aminoglycoside antibiotic, and some chemical bonds in its molecular structure may be oxidized by ROS. For example, hydroxyl radicals can react with carbon-carbon double bonds, amino groups, etc. in the kasugamycin molecule, changing the molecular structure and thus enhancing its antibacterial ability. In addition, the acidic environment of cold plasma-activated water or the ionic components therein may interact with the kasugamycin molecule, changing its molecular conformation. The antibacterial activity of kasugamycin is closely related to its molecular conformation, and a suitable conformation can enable it to better bind to bacterial targets. Ions in cold plasma-activated water, such as hydrogen ions and divalent copper ions, etc., may interact with polar groups in the kasugamycin molecule, causing a change in the molecular conformation, making it more likely to bind to the 30S subunit of the bacterial ribosome, interfering with the esterase system of pathogenic bacteria's amino acid metabolism, enhancing the ability to inhibit bacterial protein synthesis, and improving the antibacterial effect. Moreover, cold plasma-activated water itself has a certain antibacterial effect. After binding with kasugamycin, it may enhance the overall antibacterial effect through a synergistic effect. The active substances in cold plasma-activated water can damage the cell membrane structure of bacteria, increase the permeability of the cell membrane, make kasugamycin more easily enter the interior of bacterial cells, act on the target, and thus improve the ability to inhibit and kill bacteria.

[0082] Cold plasma-activated water contains reactive oxygen species and reactive nitrogen species, has antibacterial effects, and can also provide a stable environment for pesticides to enhance the bactericidal effect. Long-chain unsaturated fatty acid amides can inhibit the bacterial type III secretion system (T3SS) and block the secretion of virulence proteins. When the two are combined, cold plasma-activated water may be able to enhance the stability of long-chain unsaturated fatty acid amides through its active substances, reduce their degradation in the environment, and enable them to more persistently inhibit T3SS. The property of cold plasma-activated water to damage the bacterial cell membrane may assist long-chain unsaturated fatty acid amides to more smoothly enter the interior of bacterial cells, enhance the inhibitory ability against bacteria, and thus produce a synergistic effect in the antibacterial effect. Long-term use of a single agent is likely to cause bacteria to develop drug resistance. Cold plasma-activated water modifies kasugamycin, changing its chemical structure and antibacterial mechanism. Long-chain unsaturated fatty acid amides inhibit bacterial virulence through unique action targets. The combined use of the two may make it difficult for bacteria to resist simultaneously through a single drug resistance mechanism, thus delaying the generation of drug resistance, and there is a possibility of synergy in delaying bacterial drug resistance.

[0083] Those of ordinary skill in the art should understand that: the discussion of any of the above embodiments is only exemplary and is not intended to imply that the scope of the present invention is limited to these examples; under the concept of the present invention, the technical features in the above embodiments or different embodiments can also be combined, the steps can be implemented in any order, and there are many other variations in different aspects of the present invention as described above, which are not provided in detail for the sake of brevity.

[0084] The present invention is intended to cover all such substitutions, modifications and variations that fall within the broad scope of the appended claims. Therefore, any omissions, modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.

Claims

1. A composition containing long-chain unsaturated fatty acid amide and kasugamycin, characterized in that, The composition containing long-chain unsaturated fatty acid amide and kasugamycin is used to prepare any one of wettable powders, suspending agents, emulsifiable concentrates, microemulsions and water dispersible granules; The composition containing long-chain unsaturated fatty acid amide and kasugamycin includes the following active ingredients: long-chain unsaturated fatty acid amide, kasugamycin.

2. The composition containing long-chain unsaturated fatty acid amide and kasugamycin according to claim 1, characterized in that, The long-chain unsaturated fatty acid amide is one or more of erucamide, (E)-13-docosenamide, 13-tetradecenoic acid amide.

3. A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin, characterized in that, The composition containing long-chain unsaturated fatty acid amide and kasugamycin is the composition containing long-chain unsaturated fatty acid amide and kasugamycin described in any one of claims 1-2. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin when used to prepare wettable powder is as follows: Mix kasugamycin, long-chain unsaturated fatty acid amide, dispersant, wetting agent, thickener, preservative and filler evenly, pulverize them by air flow to a particle size ≤ 5 μm, and pass through a 200-mesh sieve to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing wettable powder.

4. The preparation method of the composition containing long-chain unsaturated fatty acid amide and kasugamycin according to claim 3, characterized in that, The mass ratio of kasugamycin, long-chain unsaturated fatty acid amide, dispersant, wetting agent, thickener, preservative and filler is 14-16:7-9:4-6:2-4:0.7-0.9:0.15-0.25:67-69.

5. A method for preparing a composition containing long-chain unsaturated fatty acid amide and kasugamycin, characterized in that, The composition containing long-chain unsaturated fatty acid amide and kasugamycin is the composition containing long-chain unsaturated fatty acid amide and kasugamycin described in any one of claims 1-2. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin when used to prepare suspending agent is as follows: Add kasugamycin, long-chain unsaturated fatty acid amide, dispersant and wetting agent to deionized water, stir and disperse evenly, grind them by a sand mill to an average particle size ≤ 2 μm, and add thickener and stabilizer to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing suspending agent.

6. The preparation method of the composition containing long-chain unsaturated fatty acid amide and kasugamycin according to claim 5, characterized in that, The mass ratio of kasugamycin, long-chain unsaturated fatty acid amide, dispersant, wetting agent, deionized water, thickener and stabilizer is 9-11:4-6:3-5:2-4:72-73:0.45-0.55:4-6.

7. A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin, characterized in that, The composition containing long-chain unsaturated fatty acid amide and kasugamycin is the composition containing long-chain unsaturated fatty acid amide and kasugamycin described in any one of claims 1-2. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin when used to prepare emulsifiable concentrate is as follows: Add long-chain unsaturated fatty acid amide and kasugamycin to a solvent, stir to dissolve them fully, then add an emulsifier, and continue to stir and mix evenly to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing emulsifiable concentrate; The mass ratio of long-chain unsaturated fatty acid amide, kasugamycin, solvent and emulsifier is 87-89:10-14:55-65:18-22.

8. A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin, characterized in that, The composition containing long-chain unsaturated fatty acid amide and kasugamycin is the composition containing long-chain unsaturated fatty acid amide and kasugamycin according to any one of claims 1-2. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a microemulsion is as follows: First, dissolve the long-chain unsaturated fatty acid amide and kasugamycin in a cosolvent to form a uniform solution. Then, add an emulsifier under stirring conditions and continue stirring to fully mix the system. Finally, add water to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a microemulsion.

9. The preparation method of the composition containing long-chain unsaturated fatty acid amide and kasugamycin according to claim 8, characterized in that, The mass ratio of the long-chain unsaturated fatty acid amide, kasugamycin, cosolvent, emulsifier and water is 8-12:8-12:4-6:14-16:58-62.

10. A preparation method of a composition containing long-chain unsaturated fatty acid amide and kasugamycin, characterized in that, The composition containing long-chain unsaturated fatty acid amide and kasugamycin is the composition containing long-chain unsaturated fatty acid amide and kasugamycin according to any one of claims 1-2. The preparation process of the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule is as follows: Mix the long-chain unsaturated fatty acid amide, kasugamycin, dispersant, wetting agent, disintegrant, binder and filler evenly, and pulverize the mixture to a particle size of 0.25-0.42 mm by air flow pulverization, and granulate by spray drying to obtain the composition containing long-chain unsaturated fatty acid amide and kasugamycin for preparing a water dispersible granule; The mass ratio of the long-chain unsaturated fatty acid amide, kasugamycin, dispersant, wetting agent, disintegrant, binder and filler is 14-16:8-12:4-6:2-4:4-6:1.8-2.2:58-62.